RESULTS OF ADJUVANT PACLITAXEL AND CARBOPLATIN AFTER CONCURRENT CHEMO RADIATION (CCRT) IN LOCALLY ADVANCED CERVICAL CANCER (LACC)

B.K. Shewalkar, Jitendra Patel Punita Pant, Roopa B. And H. Khadilkar
2020 Zenodo  
Concurrent chemo radiation (CCRT) is the standard treatment for locally advanced cervical cancer (LACC) FIGO stage IIB-IVA.However, failure rate after treatment is still as high as 30% to 40% of which local and distant failures are 17% and 18% respectively and the 5-year survival is still poor.Aim of incorporating adjuvant chemotherapy (ACT) is to target the residual disease in the pelvis and to treat occult disease outside the pelvis. Objective: This study aims to evaluate the feasibility and
more » ... he feasibility and benefit of adjuvant chemotherapy (ACT) after CCRT in such patients to the improve treatment outcome. Material and Methods: From July 2017-June 2018, eighty patients of LACC were prospectively evaluated. All patients received radiation upto 50Gy with Cisplatin 40 mg/ m2 followed by intra-cavitary radiotherapy- 3fractions of 7 Gy each (28 Gy equivalent). Adjuvant chemotherapy with Paclitaxel (175 mg/m2) +Carboplatin (AUC 5) was planned for all patients to a median of four cycles (range 3?6 cycles). Results: Eighty evaluable patients were enrolled for adjuvant chemotherapy. Disease-free survival after a median follow-up of 14 months (range 8-20) was 83.75% showing a significantly long term tumor control. The adjuvant chemotherapy was well tolerated. Hematologic and neurologic toxicities were most common side effects in our study however, they were manageable. Conclusion: Incorporating adjuvant chemotherapy with Paclitaxel and Carboplatin after concomitant chemoradiation is effective, safe and may be a very promising treatment protocol for advanced cervical cancer.
doi:10.5281/zenodo.3842741 fatcat:2chvhuf2djfixomlqoz3p3byei